Radiation-induced malignant meningioma following proton beam therapy for a choroidal melanoma

We report the first clinical case on the successful use of proton beam therapy in the management of malignant transformation of intracranial epidermoid cyst. A 43-year-old man was initially diagnosed as this disease with left facial paresis, hypesthesia and hypoalgesia in the territories of the trigeminal nerve. After failure of surgical interventions, he was referred to our radiation centre. We performed a postoperative proton beam therapy for treatment. We delivered a total dose of 57 GyE in 31 fractions. He tolerated the treatment well with mild acute toxicities and remained healthy and functional by 2-year follow-up postradiotherapy. No evidence of delayed radiation-induced neurotoxicity was observed.

Download Full-text

Proton Beam Therapy of Parapapillary Choroidal Melanoma

American Journal of Ophthalmology ◽

10.1016/j.ajo.2014.02.032 ◽

2014 ◽

Vol 157 (6) ◽

pp. 1258-1265 ◽

Cited By ~ 20

Author(s):

Aline I. Riechardt ◽

Dino Cordini ◽

Gregor D. Willerding ◽

Inna Georgieva ◽

Andreas Weber ◽

...

Keyword(s):

Proton Beam ◽

Choroidal Melanoma ◽

Proton Beam Therapy

Download Full-text

Clinical and Volumetric Outcomes of Gated Proton Beam Therapy for Choroidal Melanoma in Korea

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2016.06.1562 ◽

2016 ◽

Vol 96 (2) ◽

pp. E370

Author(s):

E.C. Choi ◽

J. Park ◽

D. Shin ◽

J.Y. Kim ◽

J.H. Kim ◽

...

Keyword(s):

Proton Beam ◽

Choroidal Melanoma ◽

Proton Beam Therapy

Download Full-text

Intravitreal Dexamethasone Implant (Ozurdex®) for Exudative Retinal Detachment after Proton Beam Therapy for Choroidal Melanoma

European Journal of Ophthalmology ◽

10.5301/ejo.5000940 ◽

2017 ◽

Vol 27 (5) ◽

pp. 596-600 ◽

Cited By ~ 1

Author(s):

Ariane Malclès ◽

Anh-Minh Nguyen ◽

Thibaud Mathis ◽

Jean-Daniel Grange ◽

Laurent Kodjikian

Keyword(s):

Visual Acuity ◽

Retinal Detachment ◽

Proton Beam ◽

Safety Profile ◽

Choroidal Melanoma ◽

Case Series ◽

Proton Beam Therapy ◽

Exudative Retinal Detachment ◽

Dexamethasone Implant

Purpose To evaluate the efficacy and safety of intravitreal 0.7-mg dexamethasone implant (DEX-I) (Ozurdex®) in the treatment of extensive exudative retinal detachment (RD) associated with uveal melanoma treated using proton beam therapy (PBT). Methods Data from 10 patients with exudative RD after PBT treated with intravitreal injection of 0.7-mg DEX-I were reviewed retrospectively. The main outcome measures were resolution of exudative RD, visual acuity, and safety profile. Results Mean age was 55.6 years (range 34-85). Mean time between PBT and DEX-I was 12.4 months (range 3-25). Mean follow-up was 9.9 months (range 4-15). Intravitreal Ozurdex® reduced exudative RD in 7 cases (70%) on average 3.1 months after injection with complete resolution of RD in 6 of these (60%). For half of the patients, their level of vision remained stable; the other half experienced a deterioration in visual acuity at the end of follow-up. No adverse effects were observed. Conclusions In this small case series, treatment with intravitreal DEX-I reduced exudative RD in the majority of cases and had an acceptable safety profile.

Download Full-text